Metoprolol Succinate Extended Release Tablets

Pays: Nouvelle-Zélande

Langue: anglais

Source: Medsafe (Medicines Safety Authority)

Ingrédients actifs:

Metoprolol succinate 23.75mg equivalent to metoprolol tartrate 25mg

Disponible depuis:

AFT Pharmaceuticals Ltd

DCI (Dénomination commune internationale):

Metoprolol succinate 23.75 mg (equivalent to metoprolol tartrate 25mg)

Dosage:

23.75 mg

forme pharmaceutique:

Modified release tablet

Composition:

Active: Metoprolol succinate 23.75mg equivalent to metoprolol tartrate 25mg Excipient: Cellulose acetate Crospovidone Glyceryl monostearate Hypromellose Methacrylic acid copolymer Microcrystalline cellulose Opadry clear YS-1-7006 Opadry white YS-1-7003 Poloxamer 188 Polysorbate 80 Sugar spheres

Type d'ordonnance:

Prescription

Fabriqué par:

Watson Pharma Private Limited

indications thérapeutiques:

Metoprolol Succinate Extended-Release Tablets are indicated for the treatment of: Hypertension - to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.

Descriptif du produit:

Package - Contents - Shelf Life: Bottle, plastic, HDPE bottle with PP cap - 100 tablets - 36 months from date of manufacture stored at or below 25°C

Date de l'autorisation:

2016-06-24